Roche may bear losses in Russia over Gaziva

Swiss pharmaceutical giant Roche (ROG: SIX), which invested 1.5 billion roubles ($25 million) in the localization of the production of its anti-cancer drug Gaziva/Gazyvaro (obinutuzumab) in Russia in order to participate in public procurements, may not implement its plans, reports The Pharma Letter’s local correspondent.

The expensive drug was not included in the program of seven high-cost nosologies, as the Russian Ministry of Health says the manufacturer did not provide all the necessary documentation.

This has been recently confirmed by general director of the Russian office of Roche, Nenad Pavletich.